Decrease post-transplant relapse using donor-derived expanded NK-cells

In this phase I/II clinical trial, we investigated the safety and efficacy of high doses of mb-IL21 ex vivo expanded donor-derived NK cells to decrease relapse in 25 patients with myeloid malignancies receiving haploidentical stem-cell transplantation (HSCT). Three doses of donor NK cells (1 × 10(5)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciurea, Stefan O., Kongtim, Piyanuch, Soebbing, Doris, Trikha, Prashant, Behbehani, Gregory, Rondon, Gabriela, Olson, Amanda, Bashir, Qaiser, Gulbis, Alison M., Indreshpal, Kaur, Rezvani, Katayoun, Shpall, Elizabeth J., Bassett, Roland, Cao, Kai, Martin, Andrew St, Devine, Steven, Horowitz, Mary, Pasquini, Marcelo, Lee, Dean A., Champlin, Richard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727305/
https://www.ncbi.nlm.nih.gov/pubmed/34312462
http://dx.doi.org/10.1038/s41375-021-01349-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727305/
https://www.ncbi.nlm.nih.gov/pubmed/34312462
http://dx.doi.org/10.1038/s41375-021-01349-4

Ejemplares similares